Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study. Issue 7 (August 2015)

• Record Type: Journal Article
• Authors: Oriol, Albert; Giraldo, Pilar; Kotsianidis, Ioannis; Couturier, Catherine; Olie, Robert; Angermund, Ralf; Corso, Alessandro
• Is Part Of: Hematology. Volume 20:Issue 7(2015)
• Page Start: 405
• Page End: 409
• Publication Date: 2015-08
• Subjects: Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1179/1607845414Y.0000000218
• Languages: German
• ISSNs: 1024-5332

Abstract

<abstract> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <sec> <title>Objective</title> <p>Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest.</p> </sec> <sec> <title>Methods</title> <p>This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens.</p> </sec> <sec> <title>Results</title> <p>Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity.</p> </sec> <sec> <title>Conclusion</title> <p>These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.</p> </sec> </abstract>